Suppr超能文献

立体定向放射外科治疗三叉神经鞘瘤后的肿瘤控制和三叉神经功能障碍改善:系统评价和荟萃分析。

Tumor control and trigeminal dysfunction improvement after stereotactic radiosurgery for trigeminal schwannomas: a systematic review and meta-analysis.

机构信息

Neurosurgery and Neurooncology Service, Centre Hospitalier Regional Universitaire de Lille, Roger Salengro Hospital, Lille, France.

Stereotactic and Functional Neurosurgery Service and Gamma Knife Unit, CHU Timone, Marseille, France.

出版信息

Neurosurg Rev. 2021 Oct;44(5):2391-2403. doi: 10.1007/s10143-020-01433-w. Epub 2020 Nov 13.

Abstract

Trigeminal nerve schwannomas (TS) are uncommon intracranial tumors, frequently presenting with debilitating trigeminal and/or oculomotor nerve dysfunction. While surgical resection has been described, its morbidity and mortality rates are non-negligible. Stereotactic radiosurgery (SRS) has emerged with variable results as a valuable alternative. Here, we aimed at reviewing the medical literature on TS treated with SRS so as to investigate rates of tumor control and symptomatic improvement. We reviewed manuscripts published between January 1990 and December 2019 on PubMed. Tumor control and symptomatic improvement rates were evaluated with separate meta-analyses. This meta-analysis included 18 studies comprising a total of 564 patients. Among them, only one reported the outcomes of linear accelerators (Linac), while the others of GK. Tumor control rates after SRS were 92.3% (range 90.1-94.5; p < 0.001), and tumor decrease rates were 62.7% (range 54.3-71, p < 0.001). Tumor progression rates were 9.4% (range 6.8-11.9, p < 0.001). Clinical improvement rates of trigeminal neuralgia were 63.5% (52.9-74.1, p < 0.001) and of oculomotor nerves were 48.2% (range 36-60.5, p < 0.001). Clinical worsening rate was 10.7% (range 7.6-13.8, p < 0.001). Stereotactic radiosurgery for TS is associated with high tumor control rates and favorable clinical outcomes, especially for trigeminal neuralgia and oculomotor nerves. However, patients should be correctly advised about the risk of tumor progression and potential clinical worsening. Future clinical studies should focus on standard reporting of clinical outcomes.

摘要

三叉神经鞘瘤(TS)是一种不常见的颅内肿瘤,常导致严重的三叉神经和/或动眼神经功能障碍。虽然已经描述了手术切除,但它的发病率和死亡率不容忽视。立体定向放射外科(SRS)已作为一种有价值的替代方法出现,其结果各不相同。在这里,我们旨在回顾 SRS 治疗 TS 的医学文献,以研究肿瘤控制和症状改善的比率。我们在 PubMed 上检索了 1990 年 1 月至 2019 年 12 月期间发表的手稿。使用单独的荟萃分析评估肿瘤控制和症状改善的比率。这项荟萃分析包括 18 项研究,共 564 名患者。其中,只有一项报告了直线加速器(Linac)的结果,而其他则是伽玛刀(GK)。SRS 后肿瘤控制率为 92.3%(范围为 90.1-94.5;p<0.001),肿瘤缩小率为 62.7%(范围为 54.3-71,p<0.001)。肿瘤进展率为 9.4%(范围为 6.8-11.9,p<0.001)。三叉神经痛的临床改善率为 63.5%(52.9-74.1,p<0.001),动眼神经的临床改善率为 48.2%(范围为 36-60.5,p<0.001)。临床恶化率为 10.7%(范围为 7.6-13.8,p<0.001)。SRS 治疗 TS 与高肿瘤控制率和良好的临床结果相关,特别是对三叉神经痛和动眼神经。然而,应该正确告知患者肿瘤进展和潜在临床恶化的风险。未来的临床研究应侧重于临床结果的标准报告。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbb7/8490235/5d210bec4a9b/10143_2020_1433_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验